ArticleJAMA network open2021
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Rui Pei et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
45 papers cite it
this paperpooled itcites it